Health Catalyst (NASDAQ:HCAT) Given New $2.75 Price Target at Citigroup

Health Catalyst (NASDAQ:HCAT) had its price target cut by investment analysts at Citigroup from $3.25 to $2.75 in a research report issued on Friday,Benzinga reports. The brokerage currently has a “neutral” rating on the stock. Citigroup’s price objective would suggest a potential upside of 14.35% from the company’s current price.

Other equities analysts have also issued reports about the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Health Catalyst in a report on Monday, December 29th. Cantor Fitzgerald reissued a “neutral” rating and set a $4.00 price target on shares of Health Catalyst in a report on Tuesday, October 7th. William Blair restated an “outperform” rating on shares of Health Catalyst in a research note on Tuesday, November 11th. UBS Group reiterated an “outperform” rating on shares of Health Catalyst in a research report on Tuesday, November 11th. Finally, KeyCorp dropped their price target on shares of Health Catalyst from $5.00 to $4.00 and set an “overweight” rating on the stock in a research report on Wednesday, October 8th. Five analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $4.32.

Health Catalyst Stock Performance

NASDAQ:HCAT traded down $0.05 during midday trading on Friday, reaching $2.41. 69,699 shares of the company traded hands, compared to its average volume of 445,232. The firm has a market capitalization of $170.11 million, a price-to-earnings ratio of -1.51 and a beta of 1.69. The company has a fifty day moving average price of $2.56 and a 200 day moving average price of $3.08. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.88 and a quick ratio of 1.88. Health Catalyst has a twelve month low of $2.02 and a twelve month high of $7.25.

Health Catalyst (NASDAQ:HCAT) last posted its earnings results on Monday, November 10th. The company reported $0.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.05 by $0.01. The company had revenue of $76.32 million for the quarter, compared to analysts’ expectations of $75.05 million. Health Catalyst had a negative return on equity of 6.67% and a negative net margin of 34.05%. On average, analysts expect that Health Catalyst will post -0.33 EPS for the current fiscal year.

Insider Activity at Health Catalyst

In other news, Director Julie Larson-Green sold 47,997 shares of the business’s stock in a transaction dated Thursday, December 4th. The shares were sold at an average price of $2.67, for a total transaction of $128,151.99. Following the transaction, the director owned 73,573 shares in the company, valued at approximately $196,439.91. The trade was a 39.48% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, General Counsel Benjamin Landry sold 27,425 shares of the business’s stock in a transaction on Friday, December 5th. The shares were sold at an average price of $2.64, for a total transaction of $72,402.00. Following the completion of the sale, the general counsel directly owned 100,000 shares in the company, valued at $264,000. This trade represents a 21.52% decrease in their position. The disclosure for this sale is available in the SEC filing. 2.60% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Health Catalyst

A number of institutional investors and hedge funds have recently made changes to their positions in the company. First Light Asset Management LLC increased its stake in shares of Health Catalyst by 9.9% during the 3rd quarter. First Light Asset Management LLC now owns 13,436,220 shares of the company’s stock worth $38,293,000 after purchasing an additional 1,206,039 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Health Catalyst by 2.9% in the third quarter. Vanguard Group Inc. now owns 4,295,691 shares of the company’s stock valued at $12,243,000 after acquiring an additional 119,117 shares during the period. Geode Capital Management LLC grew its position in shares of Health Catalyst by 11.4% during the 2nd quarter. Geode Capital Management LLC now owns 1,662,455 shares of the company’s stock worth $6,269,000 after purchasing an additional 169,580 shares in the last quarter. Millennium Management LLC increased its stake in Health Catalyst by 2,513.3% during the 3rd quarter. Millennium Management LLC now owns 1,589,536 shares of the company’s stock worth $4,530,000 after acquiring an additional 1,528,710 shares during the period. Finally, Acadian Asset Management LLC raised its stake in Health Catalyst by 25.1% in the second quarter. Acadian Asset Management LLC now owns 1,163,785 shares of the company’s stock valued at $4,385,000 after purchasing an additional 233,556 shares in the last quarter. Institutional investors own 85.00% of the company’s stock.

About Health Catalyst

Health Catalyst (NASDAQ: HCAT) is a healthcare data and analytics technology company founded in 2008 and headquartered in Salt Lake City, Utah. The company went public in 2019 and has since focused on delivering a unified data platform that helps healthcare organizations aggregate and analyze clinical, financial and operational information.

The core of Health Catalyst’s offering is the Data Operating System (DOS), a modular data management platform that integrates disparate data sources—from electronic health records to claims and patient-generated data—into a single analytics environment.